Controversy about uterine effects and safety of SERMs: The saga continues

Menopause

Volumn 9, Issue 5, 2002, Pages 381-384

  Goldstein, Steven R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CANCER SCREENING; CELL PROLIFERATION; DRUG SAFETY; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; HUMAN; MEDICAL SOCIETY; MENOPAUSE; NONHUMAN; PELVIS; RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; TRANSVAGINAL ECHOGRAPHY; VAGINA SECRETION; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENDOMETRIUM; FEMALE; PRACTICE GUIDELINE; RISK FACTOR;

ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; PRACTICE GUIDELINES; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0036726375     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200209000-00012     Document Type: Review

References (24)

1. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-238.
2. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri [Letter]. Lancet 1988;2:563.
3. Jordan VC. Tamoxifen and endometrial cancer [Letter]. Lancet 1989;2:117-120.
4. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 1990;90:207-208.
5. Atlanta G, Pozzi M, Vincenzoni C, Vocaturo G. Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 1990;37:378-380.
6. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-120.
7. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Mulder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990;35:235-238.
8. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol 1991;42:120-123.
9. Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990;163:119-123.
10. Nasri MN, Shepard JH, Setchell ME, Lowe DG, Chard T. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470-475.
11. Anteby E, Yagel S, Zacut D, Palti Z, Hochner-Celniker D. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992;340:433-436.
12. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Obstet Gynecol 1994;170:447-451.
13. Fleischer AC, Wheeler JE, Kravitz B, Jensen C, MacDonald B. Sonographic Assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999; 18:503-512.
14. Schwartz LB, Snyder J, Horan C, Porges RF, Nachtigall LE, Goldstein SR. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal beast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1998;11:48-53.
15. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-1321.
16. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388.
17. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-44.
18. Berliere M, Radikov G, Galant C, Piette PH, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000;36:S35-S36.
19. Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18:3459-3463.
20. Love CDB, Muir BB, Scrimgeour JB, Leonard RCF, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050-2054.
21. Guerrieri JP, Elkas JC, Nash JD. Evaluating the endometrium in women on tamoxifen: a pilot study to compare a "gold standard" with an "old standard." Menopause 1997;4:6-9.
22. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995;761:355-360.
23. Goldstein SR, Sheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.
24. Cummings SR, Eckert S, Kruger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197.